

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
ACTING AS THE DESIGNATED/ELECTED OFFICE**

In re: Patent application of: Karl MULLIGAN
Derek McCORMICK
Patrick JOHNSTON

Application No: 10/579,168
(International Application No: PCT/GB2004/004788)

Filed: (International Application: 15 November 2004 (15.11.2004))

For: CANCER DIAGNOSIS AND THERAPY

MAIL STOP PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

The present application is a 35 U.S.C. § 371 of PCT/GB2004/004788. Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, submitted herewith in duplicate is a substitute PTO Form 1449 listing the references cited in the Search Report in the international phase.

It is believed that copies of the references have been or will be forwarded by the International Search Authority. The Examiner is encouraged to contact the undersigned if reference copies have not been received.

Also enclosed is a copy of a Search Report issued by the British Patent Office on March 24, 2006 in corresponding United Kingdom Patent Application No. GB 0326578.2. Copies of references are enclosed herewith for citations which are not duplicated in the International Search Report.

| | |
|---|--|
| CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.10 | |
| EXPRESS MAIL Mailing Label Number: EV320483827US | |
| Date of Deposit: September 7, 2006 | |
| I hereby certify that this correspondence, along with any paper referred to as being attached or enclosed, and/or fee, is being deposited with the United States Postal Service, "EXPRESS MAIL-POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10, on the date indicated above, and addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 | |
| Signature of person mailing page: <u>Karen M. Spina</u> | |
| Type or print name of person | |

The Examiner is respectfully requested to review the items listed on the substitute PTO Form 1449 and make them of record in the instant application as required by M.P.E.P. §609. It is requested that the Examiner initial the enclosed duplicate substitute PTO Form 1449, and return one copy to the undersigned.

This Information Disclosure Statement should not be construed as a representation that the cited references are material or that more relevant prior art does not exist.

The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application, but before the mailing date of the first Office Action on the merits. Accordingly, no certification, petition, or fee is required. However, should a fee be due, authorization is hereby provided to charge Deposit Account No. 50-0573.

Respectfully submitted,

KARL MULLIGAN *et al.*

BY 

DANIEL A. MONACO
Registration No. 30,480
DRINKER BIDDLE & REATH LLP
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103-6996
TEL.: (215) 988-3312
FAX: (215) 988-2757
Attorney for Applicants

| | | | |
|---|--|--------------------------------------|--|
| SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE U.S. PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. 36290-0409-00-US | APPLICATION NUMBER 10/579,168 (I.A. PCT/GB2004/004788) |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | FIRST NAMED INVENTOR | |
| | | Karl MULLIGAN et al. | |
| | | FILING DATE (I.A. 15 NOV 2004) | ART UNIT Not yet assigned |

U.S. PATENT DOCUMENTS

| EXAMINER INITIALS | Cite No. | DOCUMENT NUMBER | PUBLICATION DATE (MM/DD/YYYY) | NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT | PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR |
|-------------------|----------|--------------------------------|----------------------------------|--|--|
| | | Number-Kind Code (if known) | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIALS | Cite No. | FOREIGN PATENT DOCUMENT | PUBLICATION DATE (MM/DD/YYYY) | NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT | PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR | T |
|--------------------|----------|---|----------------------------------|---|---|---|
| | | Country Code-Number- Kind Code (if known) | | | | |
| | A | WO 01/53836 A2 (abstract) | 07/26/2001 | MILLENIUM PREDICTIVE MEDICINE, INC. | | |
| | B | WO 98/58958 A | 12/30/1998 | UNIVERSITY OF WASHINGTON; THE CHILDREN'S HOSPITAL OF PHILADELPHIA | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| EXAMINER SIGNATURE | | | | | DATE CONSIDERED | |

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

| | | | |
|---|--|--------------------------------------|--|
| SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE U.S. PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. 36290-0409-00-US | APPLICATION NUMBER 10/579,168 (I.A. PCT/GB2004/004788) |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | FIRST NAMED INVENTOR | |
| | | Karl MULLIGAN et al. | |
| | | FILING DATE (I.A. 15 NOV 2004) | ART UNIT Not yet assigned |

NON PATENT LITERATURE DOCUMENTS

| EXAMINER INITIALS | CITE NO. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, city and/or country where published | T |
|--------------------|----------|---|---|
| | C | BASH et al., "Rel/NF-kappaB can trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch receptors", <i>EMBO J</i> 18(10):2803-2811 (1999), and Database EMBL "Homo Sapiens transmembrane protein Jagged1 (HJ1) mRNA, complete cds." retrieved from EBI, database accession no. AF028593 | |
| | D | LINDSELL, et al., "Jagged: a mammalian ligand that activates Notch1", <i>CELL</i> 80(6):909-917 (1995) and Database EMBL "Homo Sapiens transmembrane protein Jagged1 (HJ1) mRNA, complete cds." retrieved from EBI, database accession no. AF028593 | |
| | E | LI et al., "The Human Homolog of Rat Jagged1 Expressed by Marrow Stroma Inhibits Differentiation of 32D Cells Through Interaction with Notch1", <i>Immunity</i> 8:43-55 (1998) | |
| | F | GRAY et al., "Human Ligands of the Notch Receptor", <i>American Journal of Pathology</i> 154(3):785-794 (1999) | |
| | G | MULLIGAN et al., "Expression of the MQ1 cell surface glycoprotein in human astrocytomas", <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> 39:498 (1998) (abstract) | |
| | H | MULLIGAN et al., "A 'new' glioma-associated cell surface glycoprotein", <i>British Journal of Cancer</i> 78(2):148 (1998) (abstract) | |
| | I | BOOTH et al., "Expression of Jagged/Notch family members in diverse tumors in vivo: Association in vitro with a transformed phenotype", <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> 41:474-475 (2000) (abstract) | |
| | J | SUZUKI et al., "The Expression of Notch Family Genes in Human Pancreatic Cancer", <i>Digestive Disease Week Abstracts And Itinerary Planner</i> 2003 (Abstract) | |
| | K | HAQUE et al., "Demonstration of Notch-1 and Delta-like expression in human glioma cell lines and cytotoxic effect of Notch-1 inhibition", <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> 44:1310 (2003) (abstract) | |
| | L | LI et al., "Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1" <i>Nature Genetics</i> 16:243-251 (1997) | |
| | M | ODA et al., "Identification and cloning of the human homolog (JAG1) of the rat jagged1 gene from the Alagille syndrome critical region of 20p12", <i>Genomics</i> 43:376-379 (1997) | |
| EXAMINER SIGNATURE | | DATE CONSIDERED | |

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.